Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting.

The potent growth-promoting activity of insulin-like growth factor-II (IGF-II) is highly regulated during development but frequently up-regulated in tumors. Increased expression of the normally monoallelic (paternally expressed) mouse (Igf2) and human (IGF2) genes modify progression of intestinal ad...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Harper, J, Burns, J, Foulstone, E, Pignatelli, M, Zaina, S, Hassan, A
Định dạng: Journal article
Ngôn ngữ:English
Được phát hành: 2006
_version_ 1826288934244581376
author Harper, J
Burns, J
Foulstone, E
Pignatelli, M
Zaina, S
Hassan, A
author_facet Harper, J
Burns, J
Foulstone, E
Pignatelli, M
Zaina, S
Hassan, A
author_sort Harper, J
collection OXFORD
description The potent growth-promoting activity of insulin-like growth factor-II (IGF-II) is highly regulated during development but frequently up-regulated in tumors. Increased expression of the normally monoallelic (paternally expressed) mouse (Igf2) and human (IGF2) genes modify progression of intestinal adenoma in the Apc(Min/+) mouse and correlate with a high relative risk of human colorectal cancer susceptibility, respectively. We examined the functional consequence of Igf2 allelic dosage (null, monoallelic, and biallelic) on intestinal adenoma development in the Apc(Min/+) by breeding with mice with either disruption of Igf2 paternal allele or H19 maternal allele and used these models to evaluate an IGF-II-specific therapeutic intervention. Increased allelic Igf2 expression led to elongation of intestinal crypts, increased adenoma growth independent of systemic growth, and increased adenoma nuclear beta-catenin staining. By introducing a transgene expressing a soluble form of the full-length IGF-II/mannose 6-phosphate receptor (sIGF2R) in the intestine, which acts as a specific inhibitor of IGF-II ligand bioavailability (ligand trap), we show rescue of the Igf2-dependent intestinal and adenoma phenotype. This evidence shows the functional potency of allelic dosage of an epigenetically regulated gene in cancer and supports the application of an IGF-II ligand-specific therapeutic intervention in colorectal cancer.
first_indexed 2024-03-07T02:21:13Z
format Journal article
id oxford-uuid:a3fa9b4f-3fd4-42ac-a8c6-0834a70f7f5c
institution University of Oxford
language English
last_indexed 2024-03-07T02:21:13Z
publishDate 2006
record_format dspace
spelling oxford-uuid:a3fa9b4f-3fd4-42ac-a8c6-0834a70f7f5c2022-03-27T02:30:49ZSoluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a3fa9b4f-3fd4-42ac-a8c6-0834a70f7f5cEnglishSymplectic Elements at Oxford2006Harper, JBurns, JFoulstone, EPignatelli, MZaina, SHassan, AThe potent growth-promoting activity of insulin-like growth factor-II (IGF-II) is highly regulated during development but frequently up-regulated in tumors. Increased expression of the normally monoallelic (paternally expressed) mouse (Igf2) and human (IGF2) genes modify progression of intestinal adenoma in the Apc(Min/+) mouse and correlate with a high relative risk of human colorectal cancer susceptibility, respectively. We examined the functional consequence of Igf2 allelic dosage (null, monoallelic, and biallelic) on intestinal adenoma development in the Apc(Min/+) by breeding with mice with either disruption of Igf2 paternal allele or H19 maternal allele and used these models to evaluate an IGF-II-specific therapeutic intervention. Increased allelic Igf2 expression led to elongation of intestinal crypts, increased adenoma growth independent of systemic growth, and increased adenoma nuclear beta-catenin staining. By introducing a transgene expressing a soluble form of the full-length IGF-II/mannose 6-phosphate receptor (sIGF2R) in the intestine, which acts as a specific inhibitor of IGF-II ligand bioavailability (ligand trap), we show rescue of the Igf2-dependent intestinal and adenoma phenotype. This evidence shows the functional potency of allelic dosage of an epigenetically regulated gene in cancer and supports the application of an IGF-II ligand-specific therapeutic intervention in colorectal cancer.
spellingShingle Harper, J
Burns, J
Foulstone, E
Pignatelli, M
Zaina, S
Hassan, A
Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting.
title Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting.
title_full Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting.
title_fullStr Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting.
title_full_unstemmed Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting.
title_short Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting.
title_sort soluble igf2 receptor rescues apc min intestinal adenoma progression induced by igf2 loss of imprinting
work_keys_str_mv AT harperj solubleigf2receptorrescuesapcminintestinaladenomaprogressioninducedbyigf2lossofimprinting
AT burnsj solubleigf2receptorrescuesapcminintestinaladenomaprogressioninducedbyigf2lossofimprinting
AT foulstonee solubleigf2receptorrescuesapcminintestinaladenomaprogressioninducedbyigf2lossofimprinting
AT pignatellim solubleigf2receptorrescuesapcminintestinaladenomaprogressioninducedbyigf2lossofimprinting
AT zainas solubleigf2receptorrescuesapcminintestinaladenomaprogressioninducedbyigf2lossofimprinting
AT hassana solubleigf2receptorrescuesapcminintestinaladenomaprogressioninducedbyigf2lossofimprinting